Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial
about
sameAs
A review of anti-inflammatory agents for symptoms of schizophreniaInflammatory cytokines and neurological and neurocognitive alterations in the course of schizophreniaCelecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On TrialsThe role of inflammation in schizophreniaInflammation and immunity in schizophrenia: implications for pathophysiology and treatmentThe cytokine model of schizophrenia: emerging therapeutic strategiesPostmortem evidence of cerebral inflammation in schizophrenia: a systematic reviewEfficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an updateMeta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effectsViral infection, inflammation and schizophreniaThe Application of Multiplex Biomarker Techniques for Improved Stratification and Treatment of Schizophrenia Patients.Application of Proteomic Techniques for Improved Stratification and Treatment of Schizophrenia Patients.Evidence for an immune role on cognition in schizophrenia: a systematic reviewTheranostic Biomarkers for SchizophreniaTranscriptome sequencing study implicates immune-related genes differentially expressed in schizophrenia: new data and a meta-analysis.Immunological aspects of the treatment of depression and schizophrenia.Methylation patterns in whole blood correlate with symptoms in schizophrenia patients.Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume.Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot studyEffectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review.Anti-inflammatory effects of chronic aspirin on brain arachidonic acid metabolites.Biomarkers and clinical staging in psychiatryAspirin: a review of its neurobiological properties and therapeutic potential for mental illnessSchizophrenia: a systemic disorderSoluble urokinase-type plasminogen activator receptor levels in patients with schizophreniaImaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans.Low-dose aspirin (acetylsalicylate) prevents increases in brain PGE2, 15-epi-lipoxin A4 and 8-isoprostane concentrations in 9 month-old HIV-1 transgenic rats, a model for HIV-1 associated neurocognitive disorders.Expression QTL analysis of top loci from GWAS meta-analysis highlights additional schizophrenia candidate genesImmune system gene dysregulation in autism and schizophrenia.A myelin gene causative of a catatonia-depression syndrome upon aging.Can bipolar disorder be viewed as a multi-system inflammatory disease?Potential Role of Oestrogen Modulation in the Treatment of Neurocognitive Deficits in SchizophreniaFuture perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia.Higher Plasma S100B Concentrations in Schizophrenia Patients, and Dependently Associated with Inflammatory Markers.Does Systemic Inflammation Play a Role in Pediatric Psychosis?Proteomic profiling in schizophrenia: enabling stratification for more effective treatment.Effect of epigallocatechin gallate supplementation in schizophrenia and bipolar disorder: an 8-week, randomized, double-blind, placebo-controlled study.Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume.Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trialsRETRACTED: Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients
P2860
Q22241827-786DAD2D-1A6F-4E81-9DFA-69F71446B75FQ24630651-46FC1EBB-12DB-4D05-B724-440A431F3423Q26741541-2DE30116-308B-4719-9EA6-A8EABE7BBA7DQ26779719-6239C130-A351-4F65-B077-BFDEC0124995Q26781620-22B85E2F-8456-422D-84F8-BF9C5735FA6AQ26865996-86116694-2709-4ECC-B507-D47ED8894E2FQ28077391-24039393-C78D-4E86-89A0-19BDD749B3DCQ28299995-3E65D7A4-963E-4EAB-8A9E-02311269EC9FQ28657600-14D057C7-C20E-4B1A-917D-3D6E7CE00253Q30440507-5480CFEC-C858-447B-9B3A-864455624788Q33451672-0C82C230-D3C8-48AF-8F11-79DF9A084DCEQ33453744-D12A257E-39CB-4E31-8E93-317E99CD6F8AQ33621692-1D0FF2A8-FC8A-4E27-8725-AD9AB12140C7Q33624412-CFA3D85C-1BC9-4533-A294-FEBAB702EF11Q33635637-57A865D8-3B7A-4340-B0F4-0988D45B8C93Q33721031-A3F02129-7FF1-4EA3-90BA-71F1A7BAF818Q33762454-79315BAF-1EF6-4B0B-86C8-00D935B89C3FQ33849008-5F32A9F6-E6EC-4DC1-BBE3-B9887DC67500Q33937341-4817C35C-83D4-453A-8B0F-E3880A4449E1Q34384181-4D3A4122-3349-4E4E-AC13-B02F039FF46EQ34444465-0E4C368F-86FF-4BCE-BED9-6B04188D6AF6Q34447051-1C62DED0-4166-4DDA-A6FC-13CC0631BBEEQ34626598-F7815632-92D6-424C-AD0D-AD4EA24E791DQ35323907-07D1794E-039B-4624-A69F-C0038BE2C6B9Q35369617-1B12F1F1-2C4C-403A-B708-A161F80516A7Q35742545-CED1525D-4924-41C4-BDD8-937D859C543DQ36035835-806B3D28-2A7E-4801-99AB-BDCA770A443FQ36170457-0A29F427-3FA1-4766-AA14-03090FD00C77Q36213513-51808A79-1EDA-44E3-BF82-05159B28A50EQ36238656-375890A8-535A-4EE5-A2E2-CE2D6194DC4AQ36401142-0AEA7C95-7878-49D3-99FE-BFD67113E9A0Q36661099-7C37726E-A859-409E-8455-64AD2A78573CQ36930839-8FB9A75B-D72B-4EC6-AAAB-94C596942CA9Q36986134-C53981B9-8AA7-4BF8-83D2-8E1F2EF900DBQ36986370-18BBE4A0-7AD3-40BA-A247-A44B55E20C14Q36998471-2C2A6C28-765E-42BF-8387-9F944110FA87Q37079070-7BC90F6B-3354-40D5-AAAB-CB5176A81771Q37124980-64E08355-C2E6-43B8-A6D5-C26D0144F06DQ37228346-B83D6750-4A2F-4B25-B2A3-DE2D09A57E18Q37267763-562A984E-851B-4A1C-881D-96232A334FA4
P2860
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial
@ast
Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial
@en
Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial
@nl
type
label
Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial
@ast
Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial
@en
Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial
@nl
altLabel
Adjuvant Aspirin Therapy Reduces Symptoms of Schizophrenia Spectrum Disorders
@en
prefLabel
Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial
@ast
Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial
@en
Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial
@nl
P2093
P50
P921
P3181
P356
P1476
Adjuvant Aspirin Therapy Reduces Symptoms of Schizophrenia Spectrum Disorders
@en
Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial
@en
P2093
Cobi J Heijnen
Cobi J. Heijnen
Diederick E Grobbee
Huibert Burger
Jean-Paul Selten
René S Kahn
Wijnand Laan
P3181
P356
10.4088/JCP.09M05117YEL
P407
P577
2010-05-01T00:00:00Z
2010-05-15T00:00:00Z